iShares MSCI Canada (TSX) vs Iovance Biotherapeutics Inc. Common Stock — how do they compare? iShares MSCI Canada (TSX) trades at $58.3 (market cap $7.14B), while Iovance Biotherapeutics Inc. Common Stock trades at $13.36 (market cap $5.85B). The key difference: iShares MSCI Canada (TSX) is the larger of the two by market cap, and Iovance Biotherapeutics Inc. Common Stock is trading nearer its 52-week high, iShares MSCI Canada (TSX) nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Canada (TSX) for 57 Days and Iovance Biotherapeutics Inc. Common Stock for 0 Days on average.
| EWC | IOVA | |
|---|---|---|
Market Cap | $7.14B | $5.85B |
Volume | 2,496,812 | 14,517,176 |
Sector | Broad Market / Factor | Health |
52-Week High | $62.64 | $14.82 |
52-Week Low | $49.72 | $1.81 |
Typical Hold Time | 57 Days | 0 Days |
Enterprise Value | — | $5.78B |
Signals from Pluang's Aura AI — not financial advice
EWC is trading at $57.94, down 2.1% with a bearish technical signal as moving averages indicate selling pressure while oscillators remain neutral. The stock shows oversold conditions with RSI readings below 30, suggesting potential for near-term bounce. Recent news highlights Canada's trade tensions with the US and potential EU associate membership discussions creating market uncertainty.
The outlook remains cautious given trade policy risks and technical weakness, though oversold conditions may provide short-term opportunities. Key risks include US-Canada trade disputes and economic sensitivity to external shocks, while potential EU alignment could offer diversification benefits if negotiations progress favorably.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
EWC is a country-specific ETF that tracks the performance of the Canadian equity market. It provides exposure to large and mid-sized companies in Canada, with heavy concentrations in financials and energy, including Royal Bank of Canada, Shopify, and Enbridge.
Read more on EWC →Iovance Biotherapeutics develops cell therapies for cancer. Its approach uses tumor-infiltrating lymphocytes, or TIL, to target solid tumors.
Read more on IOVA →